179 related articles for article (PubMed ID: 36330532)
1. Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Learnings and Observations Regarding Alpelisib Initiation and Rechallenge.
Leung M; Rodrigues P; Roitman D
Onco Targets Ther; 2022; 15():1309-1315. PubMed ID: 36330532
[TBL] [Abstract][Full Text] [Related]
2. Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature.
Carrillo M; Rodriguez RM; Walsh CL; Mcgarvey M
AACE Clin Case Rep; 2021; 7(2):127-131. PubMed ID: 34095470
[TBL] [Abstract][Full Text] [Related]
3. Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer.
Abufaied M; Jumbo U; Alqalalwah A; Hamad MK
Cureus; 2021 Nov; 13(11):e19441. PubMed ID: 34909343
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter-2 inhibitors for hypergycemia in phosphoinositide 3-kinase pathway inhibition.
Weintraub MA; Liu D; DeMatteo R; Goncalves MD; Flory JH
Breast Cancer Res Treat; 2024 Jan; 203(1):85-93. PubMed ID: 37704834
[TBL] [Abstract][Full Text] [Related]
5. DIABETIC KETOACIDOSIS ASSOCIATED WITH ALPELISIB TREATMENT OF METASTATIC BREAST CANCER.
Farah SJ; Masri N; Ghanem H; Azar M
AACE Clin Case Rep; 2020; 6(6):e349-e351. PubMed ID: 33244501
[TBL] [Abstract][Full Text] [Related]
6. Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient.
Fugere T; Roy AM; Makhoul I
Cureus; 2021 Nov; 13(11):e19295. PubMed ID: 34900474
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransporter-2 Inhibitors for Hyperglycemia in Phosphoinositide 3-kinase Pathway Inhibition.
Weintraub MA; Liu D; DeMatteo R; Goncalves MD; Flory J
Res Sq; 2023 Mar; ():. PubMed ID: 36993733
[TBL] [Abstract][Full Text] [Related]
8. Alpelisib-Induced Diabetic Ketoacidosis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and Review of the Literature.
Ziegengeist JL; Elmes JB; Strassels SA; Patel JN; Moore DC
Clin Breast Cancer; 2024 Jun; 24(4):e204-e209. PubMed ID: 38245400
[TBL] [Abstract][Full Text] [Related]
9. Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer.
Al Zeyoudi J; El Kebbi I; Al Zaabi F; Hashmi S
Cureus; 2021 Dec; 13(12):e20817. PubMed ID: 35141074
[TBL] [Abstract][Full Text] [Related]
10. S.U.G.A.R: A Case to Outline Tactics for the Prevention of Alpelisib-Induced Hyperglycemia.
Thomas K; Germain M; Loch MM
J Investig Med High Impact Case Rep; 2022; 10():23247096221105249. PubMed ID: 35712858
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 Precipitating Euglycaemic Diabetic Ketoacidosis with SGLT2 Inhibitor Use.
Fang J; Genco M; Caskey RN
Eur J Case Rep Intern Med; 2020; 7(11):001943. PubMed ID: 33194873
[TBL] [Abstract][Full Text] [Related]
12. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Colacci M; Fralick J; Odutayo A; Fralick M
Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
14. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
Diaz-Ramos A; Eilbert W; Marquez D
Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
[TBL] [Abstract][Full Text] [Related]
15. A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.
Patel K; Nair A
Cureus; 2022 Sep; 14(9):e29652. PubMed ID: 36320965
[TBL] [Abstract][Full Text] [Related]
16. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
17. SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review.
Mahfooz RS; Khan MK; Al Hennawi H; Khedr A
Cureus; 2022 Jun; 14(6):e26267. PubMed ID: 35911365
[TBL] [Abstract][Full Text] [Related]
18. Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature.
Mistry S; Eschler DC
AACE Clin Case Rep; 2021; 7(1):17-19. PubMed ID: 33851013
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
[TBL] [Abstract][Full Text] [Related]
20. Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations.
Pla Peris B; Arranz Martin A; Ballesteros García A; Sebastián-Valles F; Marazuela Azpiroz M
Front Endocrinol (Lausanne); 2022; 13():802612. PubMed ID: 35178031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
